Atea Pharmaceuticals' Board rejected the acquisition proposal, believing it undervalues the company. This decision may not have an immediate impact on the stock price, as the market may have already priced in the possibility of a rejected offer. However, it could lead to potential future offers or negotiations, which may impact the stock price.